BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

25 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference

08 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

09 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

10 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

09 Jan 2022 09:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH

12 Dec 2021 09:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies

12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Jefferies 2021 Virtual London Healthcare Conference

11 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results

08 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors

08 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting

04 Nov 2021 09:40:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

20 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation

19 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting

01 Oct 2021 08:43:59 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

28 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues

23 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

08 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results

10 Aug 2021 06:30:00 By Nasdaq GlobeNewswire